King Andrew James 4

4 · Jade Biosciences, Inc. · Filed Feb 13, 2026

AI-generated summary of this filing

Updated Feb 14, 2026

Jade Biosciences (JBIO) CSO Andrew King Receives RSUs and Stock Option

What Happened

Andrew James King, Chief Scientific Officer & Head of Research and Development at Jade Biosciences (JBIO), received equity awards reported on Feb 12, 2026. The filing shows 41,250 restricted stock units (RSUs) and a derivative award representing an option for 247,500 shares; both were recorded as acquisitions at $0.00 (typical for grants).

Key Details

Transaction date: 2026-02-12; Form 4 filed 2026-02-13 (timely).
Awards: 41,250 RSUs (F1) and a right/option to purchase 247,500 shares (F2).
Price reported: $0.00 (grant/award), so no cash paid at grant.
Vesting (per footnotes):
- RSUs (F1): 1/4 vests on each of the first four anniversaries of Feb 15, 2026, subject to continued service; each RSU converts to one share when vested.
- Option (F2): 25% vests Feb 15, 2027, remaining 75% vests in equal monthly installments over the following three years, subject to continued service.
Shares owned after the transaction: Not specified in the provided excerpt of the filing.
Transaction code: "A" (award/grant). No 10b5-1, tax-withholding, or late-filing notes present in the excerpt.

Context

These are compensation awards (not open-market purchases or sales). RSUs and options are common executive compensation tools that create future equity only as they vest; they do not represent immediately tradable shares until vesting (RSUs convert to shares on vesting; options require exercise).
Such grants are routine for executives and reflect compensation/retention, not an explicit buy/sell signal.

Form 4

Period: 2026-02-12

See Remarks

Transactions

Award
Common Stock
[F1]
2026-02-12+41,250→ 386,113 total
Award
Stock Option (Right to Buy)
[F2]
2026-02-12+247,500→ 247,500 total
Exercise: $14.81Exp: 2036-02-11→ Common Stock (247,500 underlying)

Footnotes (2)

[F1]Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.
[F2]This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Signature

/s/ Elizabeth Balta, as attorney-in-fact for Andrew James King|2026-02-13

1 file